Related Experiment Video
Updated: Apr 20, 2026
05:44
Formation of Dispersible Taohong Siwu Tablets
Published on: February 3, 2023
2.2K
Formulation and evaluation of fast dissolving tablet containing domperidone ternary solid dispersion.
Dasharath M Patel1, Sweeti P Patel1, Chhagan N Patel1
1Department of Pharmaceutics and Pharmaceutical Technology, Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana, Gujarat, India.
International Journal of Pharmaceutical Investigation
|November 27, 2014
Summary
Domperidone ternary solid dispersion significantly enhanced drug dissolution and stability in fast-dissolving tablets. The optimized formulation proved stable under accelerated conditions, offering improved therapeutic potential.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
Background:
- Fast dissolving tablets (FDTs) are designed for rapid drug release.
- Domperidone's dissolution and solid dispersion stability present formulation challenges.
Purpose of the Study:
- To develop a domperidone ternary solid dispersion for enhanced dissolution and stability.
- To incorporate this dispersion into a fast-dissolving tablet.
Main Methods:
- Prepared binary and ternary solid dispersions using the fusion method.
- Characterized dispersions using solubility, dissolution, DSC, FTIR, and XRD.
- Formulated FDTs via direct compression and evaluated tablet properties.
Main Results:
- Optimized ternary solid dispersion (domperidone: Gelucire 50/13: Poloxamer 188, 1:2:1.5) showed maximum dissolution.
- Solid-state characterization confirmed solid dispersion formation.
- Ternary dispersions exhibited superior stability over binary dispersions.
- FDTs with 4% Crospovidone achieved 100% dissolution within 30 min.
Conclusions:
- Ternary agents improve domperidone dissolution and solid dispersion stability.
- The developed fast-dissolving tablet containing ternary solid dispersion is stable for one month under accelerated conditions.
Related Concept Videos
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
406
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
406
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
227
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
227
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
799
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
799
01:27Drug Delivery Systems: Different Types
365
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
365
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
897
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
897
01:14Drug Dissolution: Requirements and Profile Comparison
463
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
463